



ASX Release

12 October 2018

**ZELDA THERAPEUTICS LIMITED**  
ACN 103 782 378

Level 26  
140 St Georges Terrace,  
Perth Western Australia 6000  
Tel: +61 8 6558 0886  
Fax: +61 8 6316 3337  
enquiries@zeldatherapeutics.com  
www.zeldatherapeutics.com

**Contacts:**

**Zelda Therapeutics**

Dr Richard Hopkins  
Managing Director  
+61 405 656 868  
rhopkins@zeldatherapeutics.com

Monsoon Communications  
Rudi Michelson  
+61 3 9620 3333  
rudim@monsoon.com

**Directors**

Dr Richard Hopkins  
Mr Harry Karelis  
Dr Stewart Washer  
Ms Mara Gordon  
Mr Jason Peterson

**Tickers:**

Australia (ASX): ZLD  
USA (OTCQB): ZLDAF

**Ordinary Shares:**

755,341,934

**Options:**

49,000,000

1,500,000 (\$0.04 – 6/2/2020)  
\*4,500,000 (\$0.04 – 6/2/2020)  
1,000,000 (\$0.125 – 22/8/2021)  
\*2,000,000 (\$0.125 – 22/8/2021)

40,000,000 (\$0.03125 – 17/11/2021)

\* subject to vesting conditions

## Managing Director Remuneration Variation

- **Zelda building a platform for the next phase of its growth**
- **Exceptionally well positioned to continue generating shareholder value**

**Zelda Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF)** is pleased to announce that it has finalised the revised remuneration package for its Managing Director Dr. Richard Hopkins to reflect the increased workload as Zelda progresses towards the next phase of growth.

**Executive Chairman of Zelda Harry Karelis stated:**

*“Since commencing his role as Managing Director on 16 July 2018, Dr Richard Hopkins has been instrumental in maintaining Zelda’s previous strategy, whilst positioning Zelda for rapid entry into commercialisation phase upon successful clinical trials. The revised remuneration package shows how impressed the Board has been with Richards performance to date and we are confident the right choice was made with his appointment”*

A summary of the key revise terms and conditions are set out below:

**Remuneration Package**

Base Salary: \$300,000 exclusive of superannuation (effective 1 January 2019).

Options package (subject to shareholder approval):

5 million @ 10 cents per share (vesting on the date of issue)  
5 million @ 15 cents per share (vesting 16 October 2019)  
5 million @ 20 cents per share (vesting 16 October 2019)  
5 million @ 28 cents per share (vesting 16 October 2020)  
5 million @ 30 cents per share (vesting 16 October 2020)

Options expiry: 3 years from issue date

**Tim Slate**  
**Company Secretary**

**About Zelda Therapeutics ([www.zeldatherapeutics.com](http://www.zeldatherapeutics.com))**

Zelda Therapeutics Ltd is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-armed strategy comprising:

- A **human clinical trial programme** focused on insomnia, autism with activities in Australia and the USA.
- A **pre-clinical research programme** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

It has partnered with the world’s leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer and cognitive decline.